top of page

Dr Sarah Prinsloo PhD, M.A., LMFT-S, LPC, BCN-L

Bringing the Latest Science to Cancer Survivors Today

Dr. Sarah Prinsloo, enjoyed a 15 year career as a faculty member and applied neuroscientist at The University of Texas MD Anderson Cancer Center, with appointments in both Palliative, Rehabilitation, and Integrative Medicine and the Department of Neurosurgery.  She is a board member of the BCIA, the organization that certifies practitioners and sets standards for clinical practice of neurofeedback.

 

She holds degrees from the University of Houston and St. Mary's University and completed postdoctoral training in integrative oncology and biomedical imaging. Dr. Prinsloo is also a licensed marriage and family therapist with extensive teaching, research, and clinical experience. 

 

Her research focuses on neuromodulation, pain and cancer-related symptom management, and she has published widely and received numerous honors and research grants. 

Dr Sarah Prinsloo PhD, M.A., LMFT-S, LPC, BCN-L, licensed in Texas and board member of the BCIA

Selected Publications

  • Prinsloo S, Kaptchuk TJ, De Ridder D, Lyle R, Bruera E, Novy D, Barcenas CH, Cohen LG. Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Cancer. 2024 Jan;130(2):300-311. doi: 10.1002/cncr.35027. Epub 2023 Sep 21. PMID: 37733286. 
    https://pubmed.ncbi.nlm.nih.gov/37733286/
    ​

  •  Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, Lopez G, Li Y, Cohen L. The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. J Pain Symptom Manage. 2018 May;55(5):1276-1285. doi: 10.1016/j.jpainsymman.2018.01.010. Epub 2018 Feb 5. PMID: 29421164.  
    https://pubmed.ncbi.nlm.nih.gov/29421164/​
    ​

  • Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, McQuade J, Lopez G, Cohen L. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 Jun 1;123(11):1989-1997. doi: 10.1002/cncr.30649. Epub 2017 Mar 3. PMID: 28257146; PMCID: PMC5470539.
    https://pubmed.ncbi.nlm.nih.gov/28257146/
     

  • Prinsloo S, Gabel S, Lyle R, Cohen L. Neuromodulation of cancer pain. Integr Cancer Ther. 2014 Jan;13(1):30-7. doi: 10.1177/1534735413477193. Epub 2013 Feb 25. PMID: 23439659.  
    https://pubmed.ncbi.nlm.nih.gov/23439659/
     

  • Prinsloo S, Novy D, Driver L,  Ramondetta L, Eng C, Lopez G, Lee R, Lyle R, Cohen L. Neurofeedback to treat chemotherapy-induced peripheral neuropathy (CIPN), Journal of Pain, 2016.
    https://www.jpain.org/article/S1526-5900(16)00492-2/fulltext
    https://www.foundationforpn.org/neurofeedback-to-treat-chemotherapy-induced-peripheral-neuropathy/

    ​

  • Mulholland, M.M., Prinsloo, S., Kvale, E. et al. Behavioral and biologic characteristics of cancer-related cognitive impairment biotypes. Brain Imaging and Behavior 17, 320–328 (2023).
    https://doi.org/10.1007/s11682-023-00774-6
     

  • ​Kesler SR, Henneghan AM, Prinsloo S, Palesh O and Wintermark M (2023) Neuroimaging based biotypes for precision diagnosis and prognosis in cancer-related cognitive impairment. Front. Med. 10:1199605. https://doi.org/10.3389/fmed.2023.1199605

Sample of Grant Funding

Title:   Understanding and preventing cortical changes related to chemotherapy-induced peripheral neuropathy

Funding Source:  Rising Tide Foundation, MD Anderson Cancer Center IRG, 2024-2025, Principal Investigator

 

Title:   Optimizing treatments for chemotherapy-induced peripheral neuropathy

Funding Source:  American Cancer Society/Rising Tide Foundation, 2019 - 2025, Principal Investigator

​

Title: Registry study for Transcranial Magnetic Stimulation in brain tumor patients

Funding Source: Nexstim Corporation, 2021-2026, Principal Investigator

​

Title:   A Combination therapy to treat cancer-related fatigue

Funding Source:  NIH/NCI, 2018 - 2023, Co-Investigator

​

Title: Neuromodulation as a treatment for chemotherapy-induced peripheral neuropathy

Funding Source: National Center for Complementary and Integrative Health, 2014-2019, Principal Investigator

​​

Title: Biomarker identification and design of a neuromodulatory treatment program for the management of chronic                   neuropathic pain in cancer patients

Funding Source:  American Cancer Society, Hille Foundation, 2011 - 2012, Principal Investigator

bottom of page